Grifols, S.A. (NASDAQ:GRFS – Get Free Report) was the target of a significant decline in short interest in September. As of September 30th, there was short interest totalling 4,570,000 shares, a decline of 9.7% from the September 15th total of 5,060,000 shares. Approximately 1.8% of the company’s stock are sold short. Based on an average daily volume of 1,470,000 shares, the days-to-cover ratio is currently 3.1 days.
Grifols Stock Down 0.2 %
GRFS traded down $0.02 during trading hours on Wednesday, hitting $8.49. 456,025 shares of the company’s stock were exchanged, compared to its average volume of 1,988,275. The stock has a market cap of $5.84 billion, a price-to-earnings ratio of 8.32 and a beta of 0.50. Grifols has a 1-year low of $5.30 and a 1-year high of $12.15. The stock’s 50-day moving average is $8.52 and its two-hundred day moving average is $7.65. The company has a quick ratio of 0.80, a current ratio of 1.68 and a debt-to-equity ratio of 1.06.
Grifols (NASDAQ:GRFS – Get Free Report) last announced its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.21). The firm had revenue of $1.96 billion during the quarter. Sell-side analysts predict that Grifols will post 0.79 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
About Grifols
Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.
Read More
- Five stocks we like better than Grifols
- How to Use the MarketBeat Excel Dividend Calculator
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.